250 related articles for article (PubMed ID: 35293692)
21. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Liu Z; Williams M; Stewart J; Glisson BS; Fuller C; Roy-Chowdhuri S
Cancer Cytopathol; 2022 Feb; 130(2):110-119. PubMed ID: 34375025
[TBL] [Abstract][Full Text] [Related]
22. Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
Bozzetti C; Squadrilli A; Nizzoli R; Lagrasta C; Gasparro D; Majori M; Filippo M; Becchi G; Azzoni C; Campanini N; Pedrazzi G; Zavani A; Silini EM; Tiseo M; Gnetti L
Immunotherapy; 2020 Feb; 12(3):183-193. PubMed ID: 32066299
[No Abstract] [Full Text] [Related]
23. Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
Sakata KK; Midthun DE; Mullon JJ; Kern RM; Nelson DR; Edell ES; Schiavo DN; Jett JR; Aubry MC
Chest; 2018 Oct; 154(4):827-837. PubMed ID: 30059678
[TBL] [Abstract][Full Text] [Related]
24. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
[TBL] [Abstract][Full Text] [Related]
25. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Udall M; Rizzo M; Kenny J; Doherty J; Dahm S; Robbins P; Faulkner E
Diagn Pathol; 2018 Feb; 13(1):12. PubMed ID: 29426340
[TBL] [Abstract][Full Text] [Related]
27. Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Zou Y; Xu L; Tang Q; You Q; Wang X; Ding W; Zhao J; Ren G
BMC Cancer; 2020 Apr; 20(1):344. PubMed ID: 32321471
[TBL] [Abstract][Full Text] [Related]
28. False-negative programmed death-ligand 1 immunostaining in ethanol-fixed endobronchial ultrasound-guided transbronchial needle aspiration specimens of non-small-cell lung cancer patients.
Koomen BM; Vreuls W; de Boer M; de Ruiter EJ; Hoelters J; Vink A; Willems SM
Histopathology; 2021 Oct; 79(4):480-490. PubMed ID: 33772818
[TBL] [Abstract][Full Text] [Related]
29. Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Capizzi E; Ricci C; Giunchi F; Zagnoni S; Ceccarelli C; Gómez BUÁ; Casolari L; Gelsomino F; Trisolini R; Fiorentino M; Ardizzoni A
Lung Cancer; 2018 Dec; 126():9-14. PubMed ID: 30527198
[TBL] [Abstract][Full Text] [Related]
30. Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens.
Hendry S; Byrne DJ; Christie M; Steinfort DP; Irving LB; Wagner CA; Ellwood T; Cooper WA; Fox SB
Cytopathology; 2020 Mar; 31(2):90-95. PubMed ID: 31808243
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 in Cytological Samples: A Review and a Practical Approach.
Tejerina E; Garca Tobar L; Echeveste JI; de Andrea CE; Vigliar E; Lozano MD
Front Med (Lausanne); 2021; 8():668612. PubMed ID: 34026795
[TBL] [Abstract][Full Text] [Related]
32. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.
Mansour MSI; Lindquist KE; Seidal T; Mager U; Mohlin R; Tran L; Hejny K; Holmgren B; Violidaki D; Dobra K; Dejmek A; Planck M; Brunnström H
Acta Cytol; 2021; 65(6):501-509. PubMed ID: 34233336
[TBL] [Abstract][Full Text] [Related]
35. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
36. PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
Lantuejoul S; Sound-Tsao M; Cooper WA; Girard N; Hirsch FR; Roden AC; Lopez-Rios F; Jain D; Chou TY; Motoi N; Kerr KM; Yatabe Y; Brambilla E; Longshore J; Papotti M; Sholl LM; Thunnissen E; Rekhtman N; Borczuk A; Bubendorf L; Minami Y; Beasley MB; Botling J; Chen G; Chung JH; Dacic S; Hwang D; Lin D; Moreira A; Nicholson AG; Noguchi M; Pelosi G; Poleri C; Travis W; Yoshida A; Daigneault JB; Wistuba II; Mino-Kenudson M
J Thorac Oncol; 2020 Apr; 15(4):499-519. PubMed ID: 31870882
[TBL] [Abstract][Full Text] [Related]
37. A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
Tsunoda A; Morikawa K; Inoue T; Miyazawa T; Hoshikawa M; Takagi M; Mineshita M
BMC Cancer; 2019 Jun; 19(1):546. PubMed ID: 31174496
[TBL] [Abstract][Full Text] [Related]
38. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
39. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
[TBL] [Abstract][Full Text] [Related]
40. Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
Song SG; Lee J; Koh J; Kim S; Chung DH; Jeon YK
Diagn Cytopathol; 2020 Apr; 48(4):291-299. PubMed ID: 31930724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
